19.36
+3.47%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immunome
From its filings with the US Securities and Exchange Commission
Immunome is based in Bothell, Washington and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IMNM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $6.9m and a net loss of $212.4m. At that date it held total assets of $683.2m and shareholders' equity of $634.3m.
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics.
We are advancing a pipeline that includes three clinical assets and three preclinical assets. Varegacestat, formerly AL102, is an investigational, oral, once-daily gamma secretase inhibitor, or GSI. In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors. We anticipate submitting a new drug application, or NDA, in the second quarter of 2026. IM-1021, a receptor tyrosine kinase-like orphan receptor 1, or ROR1, antibody-drug conjugate, is currently under evaluation in a Phase 1 trial. In November 2025, we reported observed objective responses at multiple dose levels in B-cell lymphoma patients treated with IM-1021, and we plan to share initial data in 2026. IM-3050, a fibroblast activation protein, or FAP, targeted radioligand therapy, or RLT, received IND clearance in April 2025, and we plan to initiate a Phase 1 trial in early 2026 after delivery of third-party diagnostic radiotracer supply. Our preclinical assets include three solid tumor ADCs with anticipated 2026 IND submissions: IM-1617, IM-1340, and IM-1335.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Oct 2020
- Employees
- 177
- Website
- immunome.com ↗
- Head office
- 18702 N. CREEK PARKWAY, BOTHELL, WA, 98011
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Dr. Clay SiegallChairman of the Board, President, Chief Executive Officer, since 2023$9.2m
- Mr. Max RosettChief Financial Officer
- Dr. Phil TsaiChief Technical Officer
- Dr. Jack HigginsChief Scientific Officer$1.8m
- Ms. Sandra StonemanChief Legal Officer, General Counsel, Corporate Secretary$5.2m
- Mr. Kinney HornChief Business Officer$7.0m
- Dr. Bob LechleiderChief Medical Officer$2.9m
- Mr. Isaac BarchasLead Independent Director$82,500
- Mr. Philip WagenheimDirector, since 2017$40,000
- Mr. Jean-Jacques BienaimeIndependent Director$52,500
- Mr. James BoylanIndependent Director$55,000
- Ms. Carol SchaferIndependent Director$60,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 30
- Environment
- 30
- Social
- 47
- Governance
- 12
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immunome Inc has a strong research and development team consisting of experienced scientists and experts in immunology, providing them with the ability to effectively develop novel immunotherapies and vaccines.
- The company's extensive intellectual property portfolio gives them a competitive advantage by protecting their innovative products from competitors.
- Immunome Inc has established strategic partnerships with leading pharmaceutical companies, enabling them to access additional resources, funding, and distribution channels.
Weaknesses
- The company heavily relies on external funding sources, such as grants and partnerships, which exposes them to uncertainties and potential funding gaps.
- Immunome Inc may face challenges in effectively marketing and commercializing their products, as the immunotherapy market is highly competitive and dominated by well-established players.
- The company's success is significantly dependent on the results of their ongoing clinical trials, and any setbacks or failures could have a negative impact on their reputation and finances.
Opportunities
- The increasing demand for personalized medicine and targeted therapies presents an opportunity for Immunome Inc to leverage their expertise in immunology and develop tailored treatments.
- Advancements in technology and genomic research enable Immunome Inc to further enhance their understanding of immunology and develop more effective immunotherapies with improved safety profiles.
- The expanding global healthcare market, particularly in regions like Asia-Pacific, provides Immunome Inc with the potential to expand their reach and tap into new markets.
Threats
- Intense competition from both established pharmaceutical companies and emerging biotech firms poses a threat to Immunome Inc's market share and profitability.
- Regulatory uncertainties and evolving healthcare policies can impact the company's ability to gain necessary approvals for their products and navigate reimbursement challenges.
- Unforeseen scientific or technological breakthroughs by competitors could potentially render Immunome Inc's existing products less effective or obsolete.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.